Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating female reproductive track infection and preparation method thereof

A technology for genital tract infection and composition is applied in the field of pharmaceutical composition for treating female genital tract infection and its preparation field, which can solve the problem of not being able to protect and improve vaginal environment for a long time, destroying the balance of genital tract flora, mucosal discomfort, etc. problems, to improve blood circulation, prolong the action time of drugs, and promote healing.

Pending Publication Date: 2018-06-15
成都山信药业有限公司
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] In terms of function, gynecological medicines are basically for the purpose of sterilization, or add traditional Chinese medicine to increase their therapeutic effect. Broad-spectrum fungicides kill both pathogenic bacteria and resident probiotics, destroying the reproductive tract The balance of the flora poses a hidden danger to health; at the same time, all products ignore that gynecological diseases are likely to cause mucosal damage and cannot repair the mucosa. The drugs and devices used by patients will cause strong discomfort due to the damaged mucosa ; Unable to protect and improve the vaginal environment for a long time

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating female reproductive track infection and preparation method thereof
  • Pharmaceutical composition for treating female reproductive track infection and preparation method thereof
  • Pharmaceutical composition for treating female reproductive track infection and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Preparation of polylysine polypeptide microspheres:

[0027] Table 1 Concentration selection of emulsifier

[0028] Emulsifier mass concentration

emulsifying effect

≤2％

The emulsification effect is not good, the ball forming is poor and adhesion phenomenon occurs

3％

Good emulsifying effect, good ball forming and no adhesion

≥4

As the amount of emulsifier increases, the difficulty of demulsification and separation of microspheres increases

[0029] It can be seen from the above table that the emulsification effect of the polypeptide microspheres prepared by the emulsifier with a mass concentration of 3% is good, and the ball forming property is good without adhesion. preferred option.

[0030] On the basis of the single factor investigation, the factors affecting the particle size and distribution of the microspheres were selected, such as mass fraction of chitosan, mass ratio of polylysine to chitosan, cross-linking time,...

Embodiment 2

[0043] Preparation of polylysine microspheres in situ gel matrix:

[0044] The poloxamer was selected as the matrix of the in situ gel, and the specific models were poloxamer F127 and poloxamer F68. After dissolving the poloxamer with an appropriate amount of ultrapure water, put it in low temperature refrigeration for a period of time to prepare the poloxamer gel.

[0045] The factors affecting the formation of poloxamer gel mainly include temperature and refrigeration time. The gel conditions were optimized by single factor variables, the results are as follows:

[0046] Table 6 Single factor variable gel condition optimization

[0047] serial number

temperature °C

Refrigeration time h

Appearance

1

3

8

incomplete solubility

2

3

10

incomplete solubility

3

3

12

completely dissolved

4

4

8

completely dissolved

5

4

10

completely dissolved

6

4

12

completely dissol...

Embodiment 3

[0053] Extraction conditions and prescription screening of traditional Chinese medicine extracts:

[0054] The traditional Chinese medicine components in the present invention are Ligustrum lucidum, Sophora flavescens, Fructus Cnidii and Usnea, all of which are extracted by water.

[0055] Table 8 Ligustrum lucidum extraction conditions

[0056]

[0057] Table 9 Sophora flavescens extraction conditions

[0058]

[0059] Table 10 Fructus Cnidii Extraction Conditions

[0060]

[0061] Table 11 Usnea extraction conditions

[0062]

[0063] According to the above data, the best extraction conditions are immersion overnight, reflux extraction for 60min, and concentration by rotary evaporation. Take 100g of traditional Chinese medicine, add 1500mL of ultrapure water, reflux for extraction for 1 hour, filter, add 1500mL of ultrapure water for another 1 hour of extraction, combine the two filtrates, evaporate and concentrate to 200mL on a rotary evaporator at 50°C under...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition for treating female reproductive track infection and a preparation method thereof. The pharmaceutical composition comprises polylysine microspheres, fructus ligustri lucidi, radix sophorae flavescentis, fructus cnidii, Chinese usnea, poloxamer F127 and poloxamer F68, wherein the content of the polylysine microspheres is 0.01-0.05% by mass percent; the total content of fructus ligustri lucidi, radix sophorae flavescentis, fructus cnidii and Chinese usnea is 1-7%; the ratio of fructus ligustri lucidi to radix sophorae flavescentis to fructus cnidii to Chinese usnea is 1:1:2:1; the content of poloxamer F12 is 17-30%; the content of F68 is 0-20%; and the rest is water. After the polylysine microspheres and the traditional Chinese medicine composition are compounded, vaginal wound healing is effectively promoted. The pharmaceutical composition has a repair and regeneration promotion function on cells of a mesoderm and an ectoderm, and canpromote regeneration of blood capillaries, improve the local blood circulation and quicken wound healing. Polylysine becomes amino acid after being decomposed and can serve as a nutrient substance tobe absorbed.

Description

technical field [0001] The invention belongs to the technical field of medicines, and in particular relates to a pharmaceutical composition for treating female reproductive tract infection and a preparation method thereof. Background technique [0002] Female gynecological diseases are mostly caused by the initial genital tract infection, which is mainly caused by various opportunistic pathogenic bacteria, such as Candida albicans, Escherichia coli, staphylococcus, streptococcus, anaerobic bacteria and so on. When the autoimmune system cannot eliminate these pathogenic bacteria in time, it will easily lead to reproductive tract infection and seriously affect the health of women. At present, externally used drugs in the treatment of gynecology mainly include pure traditional Chinese medicines, antibiotics, chemical disinfectants, Chinese and Western medicines, etc., and the dosage forms include suppositories, gels, lotions, effervescent tablets, etc. [0003] In terms of fun...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/638A61K9/06A61K47/10A61P15/02A61P31/00A61K31/785
CPCA61K9/0034A61K9/06A61K31/785A61K36/09A61K36/234A61K36/489A61K36/638A61K47/10A61K2236/331A61K2236/39A61K2236/51A61K2300/00
Inventor 林山张显发胡正林伍明林·斯蒂文
Owner 成都山信药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com